Pharmax Corporation Ltd
About Pharmax Corporation Ltd
Data last updated: 06 January 2026
Pharmax Corporation Ltd is a public limited company based in New Delhi, Delhi, India, a subsidiary of Max Estates Limited. It specialises in real estate financing, a part of the broader financial services sector. Incorporated on 27 September 1989, the company has been in operation for over 37 years.
Registered with ROC Delhi under CIN U24232PB1989PLC009741.
Capital: an authorised share capital of ₹28.7 Cr and a paid-up capital of ₹8.46 Cr. It is led by directors including Benjamin Scott Greene and Archit Goyal.
Last AGM: 25 September 2025. Financial statements filed for year ended 31 March 2025. Office: Max House 1 Dr. Jha Marg Okhla New Delhi – 110020, Delhi, India – 110020.
As per the financials filed for FY 2025, the company reported a revenue of ₹41.1 Cr, reflecting significant growth compared to the previous year.
The company has a workforce of approximately 12 employees as per the latest available data. It operates as a subsidiary of Max Estates Limited.
As per MCA filings, the company has open charges of ₹249.02 Cr and satisfied charges of ₹293 Cr on record.
The current compliance status is marked as compliant by the Registrar of Companies.
-
Email*****@*****.com
-
Telephone+91-****-******
-
Website**************
-
Social Media**************
-
Registered AddressMax House 1 Dr. Jha Marg Okhla New Delhi – 110020, Delhi, India – 110020
-
IndustryFinancial Services, Real Estate Financing
- Historical Financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Litigation, compliance and MCA filings
- PDF report delivered after checkout
CIN History of Pharmax Corporation Ltd
Pharmax Corporation Ltd has 2 previous CINs, indicating changes in the company's corporate structure or registration details. The current CIN is U24232DL1989PLC458933, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| U24232DL1989PLC458933 | Current |
| U24232PB1989PLC009741 | Previous |
| L24232PB1989PLC009741 | Previous |
Business Activity of Pharmax Corporation Ltd
Pharmax Corporation Ltd is engaged in the principal business activity of real estate, with detailed activities including real estate activities with own or leased property.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| L | Real Estate | L1 | Real estate activities with own or leased property | ********* |
Auditor Details of Pharmax Corporation Ltd
Pharmax Corporation Ltd is audited by Dewan P.N. Chopra & Co. for the financial year 2023. The auditor plays a crucial role in ensuring financial transparency and compliance with accounting standards.
| Name | Status | Appointment Date | Cessation Date |
|---|---|---|---|
| Dewan P.N. Chopra & Co. | blur-value | blur-value | blur-value |
Board of Directors of Pharmax Corporation Ltd
Pharmax Corporation Ltd is currently managed by 6 directors, with 18 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
|
Benjamin Scott Greene
Also directs:
Max Towers Private Limited, Max Estates Noida Private Limited, Acreage Builders Private Limited and 2 more
|
Director | 24 Sep 2024 | 1 Years 9 Months | Current |
|
Archit Goyal
Also directs:
Max Square Limited, Max Estates Noida Two Limited, Max Estates Developers Limited and 2 more
|
Additional Director | 01 Oct 2025 | 0 Years 9 Months | Current |
|
Jillian Leigh Moo Young
Also directs:
Max Towers Private Limited, Max Estates Noida Private Limited, Acreage Builders Private Limited and 3 more
|
Director | 24 Sep 2024 | 1 Years 9 Months | Current |
| Monika Srivastava | Director | 24 Sep 2024 | 1 Years 9 Months | Current |
|
Kishansingh Ramsinghaney
Also directs:
Max Towers Private Limited, Max Asset Services Limited
|
Director | 17 Mar 1997 | 29 Years 3 Months | Current |
|
Akhil Bhalla
Also directs:
Max Towers Private Limited, Max Estates Noida Private Limited, Acreage Builders Private Limited and 1 more
|
Director | 24 Sep 2024 | 1 Years 9 Months | Current |
Financials of Pharmax Corporation Ltd FY 2025 filings available
Pharmax Corporation Ltd reported revenue of ₹41.1 Cr (up 264% YoY) for FY 2025. Profit growth despite declining revenue indicates effective cost management and margin discipline.
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue from Operations | ***** | ***** | ***** | ***** | ***** |
| Revenue Growth % | ***** | ***** | ***** | ***** | ***** |
| Other Income | ***** | ***** | ***** | ***** | ***** |
| Total Revenue | ***** | ***** | ***** | ***** | ***** |
| Expenses | |||||
| Total Expenses | ***** | ***** | ***** | ***** | ***** |
| Raw Material Cost | ***** | ***** | ***** | ***** | ***** |
| Change in Inventory FG | ***** | ***** | ***** | ***** | ***** |
| Change in Inventory WIP | ***** | ***** | ***** | ***** | ***** |
| Purchase of Traded Goods | ***** | ***** | ***** | ***** | ***** |
| Employee Cost | ***** | ***** | ***** | ***** | ***** |
| Managerial Remuneration | ***** | ***** | ***** | ***** | ***** |
| Audit Fees | ***** | ***** | ***** | ***** | ***** |
| Insurance | ***** | ***** | ***** | ***** | ***** |
| Power & Fuel | ***** | ***** | ***** | ***** | ***** |
| Interest | ***** | ***** | ***** | ***** | ***** |
| Depreciation | ***** | ***** | ***** | ***** | ***** |
| Other Expenses | ***** | ***** | ***** | ***** | ***** |
| Profitability | |||||
| EBITDA (Operating Profit) | ***** | ***** | ***** | ***** | ***** |
| Operating Margin % | ***** | ***** | ***** | ***** | ***** |
| Exceptional Items | ***** | ***** | ***** | ***** | ***** |
| Extraordinary Items | ***** | ***** | ***** | ***** | ***** |
| Profit Before Exceptional & Extraordinary Items | ***** | ***** | ***** | ***** | ***** |
| Profit Before Tax | ***** | ***** | ***** | ***** | ***** |
| Tax & Net Profit | |||||
| Tax Expense | ***** | ***** | ***** | ***** | ***** |
| Current Tax | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax | ***** | ***** | ***** | ***** | ***** |
| Profit from Discontinued Operations | ***** | ***** | ***** | ***** | ***** |
| Tax on Discontinued Operations | ***** | ***** | ***** | ***** | ***** |
| Profit | ***** | ***** | ***** | ***** | ***** |
| Net Margin % | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Shareholders' Funds | |||||
| Total Shareholders' Funds | ***** | ***** | ***** | ***** | ***** |
| Equity Capital | ***** | ***** | ***** | ***** | ***** |
| Reserves & Surplus | ***** | ***** | ***** | ***** | ***** |
| Money Against Warrants | ***** | ***** | ***** | ***** | ***** |
| Other Equity | ***** | ***** | ***** | ***** | ***** |
| Non-Current Liabilities | |||||
| Total Non-Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Long-Term Borrowings | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax Liabilities | ***** | ***** | ***** | ***** | ***** |
| Other Non-Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Long-Term Provisions | ***** | ***** | ***** | ***** | ***** |
| Current Liabilities | |||||
| Total Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Short-Term Borrowings | ***** | ***** | ***** | ***** | ***** |
| Trade Payables | ***** | ***** | ***** | ***** | ***** |
| Other Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Short-Term Provisions | ***** | ***** | ***** | ***** | ***** |
| Total Equity & Liabilities | ***** | ***** | ***** | ***** | ***** |
| Non-Current Assets | |||||
| Non-Current Assets | ***** | ***** | ***** | ***** | ***** |
| Tangible Assets | ***** | ***** | ***** | ***** | ***** |
| Intangible Assets | ***** | ***** | ***** | ***** | ***** |
| Capital WIP | ***** | ***** | ***** | ***** | ***** |
| Intangibles Under Dev | ***** | ***** | ***** | ***** | ***** |
| Investments | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax Assets | ***** | ***** | ***** | ***** | ***** |
| LT Loans & Advances | ***** | ***** | ***** | ***** | ***** |
| Other Non-Current Assets | ***** | ***** | ***** | ***** | ***** |
| Current Assets | |||||
| Current Assets | ***** | ***** | ***** | ***** | ***** |
| Current Investments | ***** | ***** | ***** | ***** | ***** |
| Inventories | ***** | ***** | ***** | ***** | ***** |
| Trade Receivables | ***** | ***** | ***** | ***** | ***** |
| Cash & Bank Balance | ***** | ***** | ***** | ***** | ***** |
| ST Loans & Advances | ***** | ***** | ***** | ***** | ***** |
| Other Current Assets | ***** | ***** | ***** | ***** | ***** |
| Total Assets | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Cash from Operating Activities (CFO) | |||||
| Profit Before Tax | ***** | ***** | ***** | ***** | ***** |
| Non-Cash Adjustments | ***** | ***** | ***** | ***** | ***** |
| + Interest Expense | ***** | ***** | ***** | ***** | ***** |
| + Depreciation | ***** | ***** | ***** | ***** | ***** |
| +/- Unrealized Forex | ***** | ***** | ***** | ***** | ***** |
| - Dividend Income | ***** | ***** | ***** | ***** | ***** |
| - Interest Income | ***** | ***** | ***** | ***** | ***** |
| +/- Other Non-Cash Items | ***** | ***** | ***** | ***** | ***** |
| Changes in Working Capital | ***** | ***** | ***** | ***** | ***** |
| +/- Inventory | ***** | ***** | ***** | ***** | ***** |
| +/- Debtors | ***** | ***** | ***** | ***** | ***** |
| +/- Creditors | ***** | ***** | ***** | ***** | ***** |
| Reconciliation Adjustments | ***** | ***** | ***** | ***** | ***** |
| Cash Generated from Operations | ***** | ***** | ***** | ***** | ***** |
| Income Taxes Paid | ***** | ***** | ***** | ***** | ***** |
| Net CFO (Cash from Operations) | ***** | ***** | ***** | ***** | ***** |
| Cash from Investing Activities (CFI) | |||||
| Acquisitions & Disposals | ***** | ***** | ***** | ***** | ***** |
| Disposal of Subsidiaries | ***** | ***** | ***** | ***** | ***** |
| Acquisition of Subsidiaries | ***** | ***** | ***** | ***** | ***** |
| Capex | ***** | ***** | ***** | ***** | ***** |
| Purchase of Fixed Assets | ***** | ***** | ***** | ***** | ***** |
| Sale of Fixed Assets | ***** | ***** | ***** | ***** | ***** |
| Other Investing Cash Flows | ***** | ***** | ***** | ***** | ***** |
| Net CFI (Cash from Investing) | ***** | ***** | ***** | ***** | ***** |
| Cash from Financing Activities (CFF) | |||||
| Equity Issuance | ***** | ***** | ***** | ***** | ***** |
| Debt Raised | ***** | ***** | ***** | ***** | ***** |
| Debt Repaid | ***** | ***** | ***** | ***** | ***** |
| Dividends Paid | ***** | ***** | ***** | ***** | ***** |
| Interest Paid | ***** | ***** | ***** | ***** | ***** |
| Net CFF (Cash from Financing) | ***** | ***** | ***** | ***** | ***** |
| Net Cash Position | |||||
| Net Change in Cash (Pre-Forex) | ***** | ***** | ***** | ***** | ***** |
| Closing Cash & Equivalents | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Liquidity | |||||
| Current Ratio | ***** | ***** | ***** | ***** | ***** |
| Quick Ratio | ***** | ***** | ***** | ***** | ***** |
| Cash Ratio | ***** | ***** | ***** | ***** | ***** |
| Efficiency | |||||
| Inventory Days | ***** | ***** | ***** | ***** | ***** |
| Debtor Days | ***** | ***** | ***** | ***** | ***** |
| Creditor Days | ***** | ***** | ***** | ***** | ***** |
| Cash Conversion Cycle | ***** | ***** | ***** | ***** | ***** |
| Asset Turnover | ***** | ***** | ***** | ***** | ***** |
| Profitability | |||||
| Net Profit Margin % | ***** | ***** | ***** | ***** | ***** |
| Operating Margin % | ***** | ***** | ***** | ***** | ***** |
| ROE % | ***** | ***** | ***** | ***** | ***** |
| ROCE % | ***** | ***** | ***** | ***** | ***** |
| Net Worth Margin % | ***** | ***** | ***** | ***** | ***** |
| Growth | |||||
| Revenue Growth % | ***** | ***** | ***** | ***** | ***** |
| Leverage | |||||
| Equity Multiplier | ***** | ***** | ***** | ***** | ***** |
| Debt / EBITDA | ***** | ***** | ***** | ***** | ***** |
| Solvency | |||||
| D/E Ratio | ***** | ***** | ***** | ***** | ***** |
| ICR | ***** | ***** | ***** | ***** | ***** |
Consolidated Statements
Income Statement, Balance Sheet, Cash Flow & Ratios available in the full report.
Shareholding Pattern of Pharmax Corporation Ltd
As of FY 2023, Pharmax Corporation Ltd's shareholding pattern shows 100.00% by promoters. The promoters hold a majority stake, indicating strong promoter control.
| Year | 2025 |
|---|---|
| Promoters | 33.19% |
| DII | 23.22% |
| FII | 18.28% |
| Public | 22.89% |
| Others | 2.42% |
Charges & Borrowings of Pharmax Corporation Ltd
| Date | Lender | Amount | Status |
|---|---|---|---|
| 20 Dec 2024 | Others | ₹97.02 Cr | Open |
| 28 Jun 2024 | Others | ₹152 Cr | Open |
| 23 Feb 2024 | Others | ₹50 Cr | Satisfied |
| 19 Oct 2022 | Others | ₹68 Cr | Satisfied |
| 10 Nov 2021 | Others | ₹65 Cr | Satisfied |
Total charge records: 8 View all charges
Employees and EPFO Compliance at Pharmax Corporation Ltd
View historical data on people associated with Pharmax Corporation Ltd, including employment history and EPFO contributions.
Employee Count & EPFO Data of Pharmax Corporation Ltd
Access employee headcount trends, monthly PF payment records, EPFO establishment details, and compliance data.
GST Compliance of Pharmax Corporation Ltd
GSTIN & GST Filing Data of Pharmax Corporation Ltd
Access GSTIN registrations, state-wise filing compliance, HSN/SAC codes, and detailed goods & services data.
Credit Ratings, Litigation & Regulatory Alerts for Pharmax Corporation Ltd
Credit Ratings, Legal Cases & Regulatory Alerts of Pharmax Corporation Ltd
Access complete credit rating history, litigation records, regulatory alerts, and compliance data.
MSME Payment Delays by Pharmax Corporation Ltd
MSME Payment Delays by Pharmax Corporation Ltd
Track payments outstanding to micro and small enterprise vendors, as disclosed in half-yearly MSME-1 returns filed with the MCA.
Subsidiaries & Group Companies of Pharmax Corporation Ltd
Subsidiaries & Group Companies of Pharmax Corporation Ltd
See the full corporate group - holding company, subsidiaries, associates and joint ventures of Pharmax Corporation Ltd with ownership details.
MCA Filings & Documents of Pharmax Corporation Ltd
MCA Filings & Documents of Pharmax Corporation Ltd
Download official documents filed with the Ministry of Corporate Affairs - from incorporation papers to the latest annual filings.
Recent Activity on Pharmax Corporation Ltd
Frequently Asked Questions about Pharmax Corporation Ltd
Pharmax Corporation Ltd is an active public limited company in the financial services sector based in New Delhi, Delhi, India. It was incorporated on 27 September 1989 (37+ years old) and is registered under CIN U24232DL1989PLC458933. The company has 12 employees.
Pharmax Corporation Ltd reported revenue of ₹41.1 Cr for FY 2025 (up 264.00% YoY).
The current directors of Pharmax Corporation Ltd are:
The primary industry of Pharmax Corporation Ltd is financial services. The company specifically operates in real estate financing. The company is currently active in this sector.
Pharmax Corporation Ltd can be reached at the registered office: Max House 1 Dr. Jha Marg Okhla New Delhi – 110020, Delhi, India – 110020.
The authorised capital is ₹28.7 Cr, and the paid-up capital is ₹8.46 Cr.